Clinical Predictive Score for Identifying Metabolic Dysfunction-Associated Steatotic Liver Disease in Individuals with Prediabetes Using Transient Elastography

• Published in: Journal of clinical medicine Vol. 12; no. 24; p. 7617
• Main Authors: Mahachai, Nutthachoke, Washirasaksiri, Chaiwat, Ariyakunaphan, Pinyapat, Kositamongkol, Chayanis, Sitasuwan, Tullaya, Tinmanee, Rungsima, Auesomwang, Chonticha, Sayabovorn, Naruemit, Chaisathaphol, Thanet, Phisalprapa, Pochamana, Charatcharoenwitthaya, Phunchai, Srivanichakorn, Weerachai
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01.12.2023
• Subjects: Atherosclerosis; Blood pressure; Body mass index; Cardiovascular disease; Clinical medicine; Diabetes; Disease prevention; Glycosylated hemoglobin; Hepatitis; Hypertension; Insulin resistance; Liver cirrhosis; Liver diseases; Metabolic disorders; Metabolic syndrome; Prediabetic state; Risk factors; Statins; Statistical analysis; Type 2 diabetes; Variables; Thailand; Asia; transient elastography; prediabetic state; screening and diagnostic method; metabolic dysfunction-associated steatotic liver disease; Thais
• ISSN: 2077-0383; 2077-0383
• DOI: 10.3390/jcm12247617

Scoring systems for metabolic dysfunction-associated steatotic liver disease (MASLD) in individuals with prediabetes have not been extensively explored. This study aimed to investigate the prevalence of MASLD and to develop predictive tools for its detection in high cardiometabolic people with prediabetes. A cross-sectional study was conducted using baseline data from the prediabetes cohort. All participants underwent transient elastography to assess liver stiffness. MASLD was defined using a controlled attenuation parameter value > 275 dB/m and/or a liver stiffness measurement ≥ 7.0 kPa. Cases with secondary causes of hepatic steatosis were excluded. Out of 400 participants, 375 were included. The observed prevalence of MASLD in individuals with prediabetes was 35.7%. The most effective predictive model included FPG ≥ 110 mg/dL; HbA1c ≥ 6.0%; sex-specific cutoffs for HDL; ALT ≥ 30 IU/L; and BMI levels. This model demonstrated good predictive performance with an AUC of 0.80 (95% CI 0.73-0.86). At a cutoff value of 4.5, the sensitivity was 70.7%, the specificity was 72.3%, the PPV was 58.8%, and the NPV was 81.5%. Our predictive model is practical, easy to use, and relies on common parameters. The scoring system should aid clinicians in determining when further investigations of MASLD are warranted among individuals with prediabetes, especially in settings with limited resources.